Knopp Biosciences

52 articles about Knopp Biosciences

• Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)

  2/28/2022

  Knopp Biosciences LLC reported further clinical data from its Phase 2 Exhale trial demonstrating oral dexpramipexole improves airflow obstruction in asthma as measured by FEV1, largely through its effect on FVC.

• Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

  9/7/2021

  Knopp Biosciences LLC reported further clinical and biomarker data demonstrating that reduction in eosinophil count by oral dexpramipexole significantly correlated with improved lung function in the positive Phase 2 EXHALE trial of dexpramipexole in patients with moderate-to-severe eosinophilic asthma.

• Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

  5/17/2021

  Dose-dependent reduction in blood eosinophil counts was accompanied by large volume improvements in lung function

• Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

  5/13/2021

  Knopp Biosciences LLC announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.

• Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

  1/14/2021

  Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks

• Knopp Biosciences NIH-Funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

  10/8/2020

  Knopp Biosciences LLC announced that it entered the second year of research funded by the National Institutes of Health to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic pain.

• Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

  9/16/2020

  Knopp Biosciences LLC announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with moderate-to-severe eosinophilic asthma.

• Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series August 18

  8/17/2020

  Knopp Biosciences LLC , a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet needs, announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series Oppenheimer’s Private Life Sciences Company Call Series to be held virtually August 17-19, 2020. Details regarding the company’s presentation are as foll

• Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

  7/15/2020

  Knopp Biosciences LLC announced that it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for its therapeutic candidate KB-3061, an activator of voltage-gated Kv7.2/7.3 potassium channels, for the treatment of KCNQ2 epileptic encephalopathy.

• 

  BioSpace Movers & Shakers, July 10

  7/10/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Knopp Biosciences Appoints Stephen E. Butts to Board of Managers

  7/8/2020

  Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced the appointment of Stephen E. Butts to its Board of Managers.

• Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

  12/9/2019

  Preclinical data support the development of KB-3061 as a potential precision medicine treatment for a rare pediatric epilepsy

• Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma

  12/2/2019

  Novel, oral eosinophil-depleting drug to be tested as a “pre-biologic” alternative treatment for reducing asthma exacerbations

• Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

  11/27/2019

  Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.

• Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference

  11/12/2019

  Company to provide update on status of ongoing Phase 2 clinical trial in eosinophilic asthma

• Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-Opioid Treatment for Chronic Pain

  9/26/2019

  Company to receive up to $8 million for its Kv7 platform as part of federal program to apply scientific solutions to reverse the national opioid crisis

• Knopp Biosciences Receives Year 4 Renewal of NIH Blueprint Grant Award for Advancing the Kv7 Activator KB-3061 in a Rare Neonatal Epilepsy

  9/25/2019

  Knopp’s lead Kv7 platform candidate advancing toward clinical studies in KCNQ2 epileptic encephalopathy

• Knopp Biosciences Reports Data Demonstrating Restoration of Function by KB-3061 in Cellular Model of Gene Variants Causing KCNQ2 Epileptic Encephalopathy

  9/17/2019

  Knopp Biosciences LLC today reported the results of preclinical experiments demonstrating that KB-3061, the lead molecule in the Company’s ion channels platform, restored the function of Kv7 potassium channels in cells engineered to express gene variants that cause the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE).

•  Knopp Biosciences to Present Data Characterizing Its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases

  9/13/2019

  Company’s lead Kv7 modulator, KB-3061, in preclinical development for KCNQ2 epileptic encephalopathy

• 

  Clinical Catch-up for August 19-23

  8/26/2019

  Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.